Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc.. - Source: Wikipedia
Five other labs quickly joined the field with their own tests, slashing costs from the $4,000 price tag Myriad Genetics had been charging when it claimed the patent to as little as a few hundred dollars.
© Copyright 2019 The Washington Times, LLC
3600 New York Avenue NE, Washington, DC 20002